PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26749359-0	2016	Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines.	Anthracyclines	89-103	BRCA1 DNA repair associated	Homo sapiens	20-25	
26749359-2	2016	Women with BRCA1/2 mutations who develop breast cancer (BC) may receive anthracyclines but their risk of cardiac dysfunction has not been investigated.	Anthracyclines	72-86	BRCA1 DNA repair associated	Homo sapiens	11-18	
26749359-3	2016	Our study tested the hypothesis that women with history of BRCA1/2 mutation-associated BC treated with anthracyclines have impaired parameters of cardiac function compared to similarly treated women with history of sporadic BC.	Anthracyclines	103-117	BRCA1 DNA repair associated	Homo sapiens	59-66	
26749359-7	2016	Mean age was 50 +- 9 years in both groups (P = 0.99) but BRCA1/2 mutation carriers had longer anthracycline treatment-to-enrollment time (7.5 +- 5.3 vs. 4.2 +- 3.3 years, P = 0.001).	Anthracyclines	94-107	BRCA1 DNA repair associated	Homo sapiens	57-62	
26749359-11	2016	In contrast to laboratory animal data, our findings indicate lack of elevated cardiac risk with the use of standard-doses of adjuvant anthracyclines in treatment of BRCA1/2 mutation carriers with early stage BC.	Anthracyclines	134-148	BRCA1 DNA repair associated	Homo sapiens	165-172